Altimmune ALT
NASDAQ ALT
$2.97 +0.01 (+0.27%)
As of: Sep 29, 2026 · 3:59 PM EDT

Altimmune (ALT) Receivables - Accured (2023 - 2026)

Updated

Altimmune (ALT) reported Receivables - Accured of $3.3 million for Q2 2026, up 135.7% from the prior quarter.

Analysis

Altimmune (ALT) Receivables - Accured (2023 - 2026) Analysis & Trends

At the end of FY2025, Altimmune posted Receivables - Accured of $1.1 million, up 175.0% from FY2024.

  • By year, Receivables - Accured came in at $400,000 in FY2024 (+300.0%) and $100,000 in FY2023.
  • The Q2 2026 figure ranks as the highest quarterly Receivables - Accured in data going back to Q4 2023.
  • Per Business Quant data, the three quarters before Q2 2026 came in at $1.4 million (Q1 2026), $1.1 million (Q4 2025) and $700,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables - Accured (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn -
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn -
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn -
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Altimmune 575.64 Mn 575.64 Mn - 3.30 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.30 Mn
Mar 31, 2026 1.40 Mn
Dec 31, 2025 1.10 Mn
Sep 30, 2025 700,000.00
Mar 31, 2025 400,000.00
Dec 31, 2024 400,000.00
Sep 30, 2024 300,000.00
Jun 30, 2024 300,000.00
Mar 31, 2024 200,000.00
Dec 31, 2023 100,000.00
API Access

Altimmune Receivables - Accured API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-accured&ticker=ALT&period=max&api_key=YOUR_API_KEY